Nikolaos Tsaftaridis

Mr. Nikolaos Tsaftaridis

Aristotle University of Thessaloniki, Thessaloníki, Kentrikí Makedonía, Greece
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
NTNikolaos Tsaftaridis
Nikolaos Tsaftaridis
MGMark Goldin
Mark Goldin
Alex C SpyropoulosAlex C Spyropoulos
Alex C Spyropoulos
Thromboprophylaxis of hospitalized patients at risk of venous thromboembolism (VTE) presents challenges owing to patient heterogeneity and lack of adoption of evidence-based methods. Intuitive practices for thromboprophylaxis have resulted in many patients being inappropriately prophylaxed. We conducted a narrative review summarizing system-wide thromboprophylaxis interventions in hospitalized patients. Multiple interventions for thromboprophylaxis have been tested, including multifaceted approaches such as national VTE prevention programs with audits, pre-printed order entry, passive alerts (either human or electronic), and more recently, the use of active clinical decision support (CDS) tools incorporated into electronic health records (EHRs). Multifaceted health-system and order entry interventions have shown mixed results in their ability to increase appropriate thromboprophylaxis and reduce VTE unless mandated through a national VTE prevention program, though the latter approach is potentially costly and effort- and time-dependent. Studies utilizing passive human or electronic alerts have also shown mixed results in increasing appropriate thromboprophylaxis and reducing VTE. Recently, a universal cloud-based and EHR-agnostic CDS VTE tool incorporating a validated VTE risk score revealed high adoption and effectiveness in increasing appropriate thromboprophylaxis and reducing major thromboembolism. Active CDS tools hold promise in improving appropriate thromboprophylaxis, especially with further refinement and widespread implementation within various EHRs and clinical workflows.

5 February 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MGMark Goldin
Mark Goldin
NTNikolaos Tsaftaridis
Nikolaos Tsaftaridis
JJJack Jnani
Jack Jnani
Alex C SpyropoulosAlex C Spyropoulos
Alex C Spyropoulos
The advent of direct-acting oral anticoagulants (DOACs) has transformed the care of patients requiring prevention and treatment for thrombotic disease. Many randomized clinical trials have demonstrated the efficacy and safety of these agents and their comparative advantages over conventional anticoagulants such as vitamin K antagonists (VKAs). While historically clinicians and patients raised questions about the reversal of DOAC-associated bleeding, federal approval in recent years of targeted DOAC reversal agents, along with adjunctive modalities, has given clinicians reliable pharmacologic options. Yet, optimal reversal strategies for bleeding at specific anatomic locations and in specific clinical scenarios remains uncertain. We present here a narrative review of the literature on the reversal of DOAC-associated bleeding or for urgent procedures. The totality of the reversal literature synthesized here yields several clear conclusions: (1) targeted DOAC reversal with specific agents demonstrates superior efficacy for both bleeding and urgent surgical indications when compared to the use of non-specific agents, such as prothrombin complex concentrates (PCCs); (2) at the same time, high-quality data suggest potentially increased thrombotic risks, particularly for ischemic stroke, when using the specific targeted agent andexanet; (3) in all cases of life-threatening bleeding, timely reversal is of the essence; (4) in particular, there is growing consensus that DOAC-associated intracranial hemorrhage (ICH) should be reversed promptly, with a goal door-to-reversal time of 60 min; (5) future research will focus on optimizing clinical pathways for reversal to address “calls to action” from professional groups on this critical topic.

11 February 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ATArgyrios Tzamalis
Argyrios Tzamalis
MFMaria Foti
Maria Foti
MGMaria Georgiadou
Maria Georgiadou
NTNikolaos Tsaftaridis
Nikolaos Tsaftaridis
NZNikolaos Ziakas
Nikolaos Ziakas
Background/Objectives: To provide insight into populations at higher risk of COVID-19-related retinal vascular occlusion, we identified the baseline characteristics of COVID-19 patients and vaccine recipients who developed this condition by conducting a systematic review to summarize the findings and evaluate the current knowledge on this subject. Methods: An electronic search on the PubMed and Scopus databases was performed for relevant case reports or series regarding retinal vascular occlusion in patients with past or present COVID-19 infection or SARS-CoV-2 immunization. This study was conducted using a pre-determined protocol following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Results: A total of 34 studies were enrolled in this systematic review. A total of 21 patients (14 males, 66.7%) have been diagnosed with COVID-19 related retinal vein occlusion (RVO, mean age = 41.9 ± 10.3 years), and 15 patients (12 males, 80%) have been diagnosed with retinal artery occlusion (RAO, mean age = 56.9 ± 13.2 years). The time to RVO since COVID-19 infection or SARS-CoV-2 immunization ranged from 8 h to 51 days (mean = 12.3 ± 15.7 days), while the time to RAO ranged from 2 to 40 days (mean = 14.9 ± 10.8 days). Fifteen out of the twenty-one patients (71.4%) with RVO had a significant improvement in visual acuity after the resolution of symptoms while eight out of the fifteen patients (53.3%) with RAO did not show improvement. Conclusions: COVID-19 seems to play a significant role in the pathogenesis of vascular occlusion, as it is suggested to increase the risk of thromboembolic episodes. However, the pathophysiologic mechanisms have not been fully elucidated, and further studies are expected to shed light on this phenomenon.

28 February 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
NTNikolaos Tsaftaridis
Nikolaos Tsaftaridis
MGMark Goldin
Mark Goldin
Alex C SpyropoulosAlex C Spyropoulos
Alex C Spyropoulos
Thromboprophylaxis of hospitalized patients at risk of venous thromboembolism (VTE) presents challenges owing to patient heterogeneity and lack of adoption of evidence-based methods. Intuitive practices for thromboprophylaxis have resulted in many patients being inappropriately prophylaxed. Multiple interventions for thromboprophylaxis have been tested, including use of multifaceted approaches such as national VTE prevention programs with audits, use of passive alerts (either human or electronic), and more recently use of active clinical decision support (CDS) tools incorporated into electronic health records (EHRs). Multifaceted health-system interventions have shown mixed results in their ability to increase appropriate thromboprophylaxis and reduce VTE, unless mandated through a national VTE prevention program, though the latter approach is potentially costly, effort- and time-dependent. Studies utilizing passive human or electronic alerts have also shown mixed results in increasing appropriate thromboprophylaxis and reducing VTE. The use of active CDS tools holds the greatest promise, especially with further refinement and widespread implementation within various EHRs and clinical workflows. Recent-ly a universal cloud-based and EHR-agnostic CDS VTE tool revealed high adoption and effectiveness in increasing appropriate thromboprophylaxis and reducing major thromboembolism. This narrative review summarizes the literature on system-wide thromboprophylaxis interventions in hospitalized patients, with a focus on CDS tools.

1 February 2026 in Brain Hemorrhages
Verified
Journal Article
Open access
Theofilos KanavosTheofilos Kanavos
Theofilos Kanavos
Effrosyni BirbasEffrosyni Birbas
Effrosyni Birbas
MGMaria Georgiadou
Maria Georgiadou
NTNikolaos Tsaftaridis
Nikolaos Tsaftaridis

7 October 2026 in SN Comprehensive Clinical Medicine
Verified
Journal Article
Open access
PDF file
MGMaria Georgiadou
Maria Georgiadou
Theofilos KanavosTheofilos Kanavos
Theofilos Kanavos
Effrosyni BirbasEffrosyni Birbas
Effrosyni Birbas
MMMaria Marinakis
Maria Marinakis
NTNikolaos Tsaftaridis
Nikolaos Tsaftaridis
Background: Cardiac surgery carries a disproportionately elevated risk of perioperative ophthalmological complications compared with other surgical procedures. Despite growing recognition of ocular and visual complications in this setting, a comprehensive synthesis of their entire spectrum has been lacking. Objective: To systematically identify, map, and characterize the full range of ocular and visual complications reported following cardiac surgery, including disorders affecting ophthalmic structures, ocular motility, or visual function. Methods: This scoping review was conducted following the Joanna Briggs Institute methodology and reported according to the PRISMA-ScR recommendations. PubMed, Embase, and Web of Science were searched from inception through January 2025 for studies reporting ocular or visual complications directly associated with heart or great vessel surgery. Evidence was charted by complication type and synthesized descriptively. Results: Our review included 115 studies, mostly case reports. The most frequently reported complications were ischemic optic neuropathy, retinal vascular occlusive disorders, cerebral visual impairment, pituitary apoplexy, midbrain ischemia, visual pseudohallucinations, Horner syndrome, endophthalmitis, supranuclear ocular motility disorders, and orbital hemorrhage. Less recognized potential complications included ocular hypotony, amaurosis fugax, chiasmal stroke, Miller Fisher syndrome, ocular ischemic syndrome, paracentral acute middle maculopathy, and retinal detachment. Based on case report data, patients were predominantly men and most often in their 6th or 7th decades of life, ischemic optic neuropathy accounted for the most events, and coronary artery bypass grafting was the most frequently implicated operation. Recurring perioperative associations with cardiopulmonary bypass, hemodynamic instability, embolic phenomena, anemia, and preexisting vascular comorbidities were observed across studies. Visual outcomes were variable, with many ischemic complications resulting in persistent deficits. Conclusions: Ocular and visual complications after cardiac surgery constitute a broad, heterogeneous group of disorders that, albeit rare, may result in substantial morbidity. Clinical awareness, perioperative vigilance, and prompt multidisciplinary evaluation may facilitate early identification and timely management.